GLP-1 / Metabolic

Retatrutide

FDA approved

Triple agonist — three receptors, one molecule, the highest weight loss efficacy ever recorded.

Mechanism

GLP-1 / GIP / glucagon triple agonist. Triple agonist — three receptors, one molecule, the highest weight loss efficacy ever recorded. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.

Peer-Reviewed Studies (3)

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2

NEJM · 2023

24.2% weight loss at 48 weeks; 26% lost ≥25%.

PubMed PMID 37351564

Retatrutide for Type 2 Diabetes — Phase 2

Lancet · 2023

HbA1c reduction of 2.02% with 16.94% weight loss.

PubMed PMID 37385280

Retatrutide and MASLD Liver Fat — Phase 2

Nature Medicine · 2024

>80% relative liver fat reduction at 48 weeks.

PubMed PMID 38641750

Related Compounds